This model suggests that the frequent deletion of SNORD50A/B observed in cancer, which is enriched for co-occurrence with oncogenic KRAS mutations16, removes a block to SNARE-facilitated KRAS trafficking to the PM where it can mediate its oncogenic signaling functions. This evidence concerns the gene KRAS and cancer.